Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTHALYA: Neoadjuvant Bevacizumab in Ovarian Cancer
NCT01739218Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2013
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Roche. Started Feb 2013; status: completed.
02
Drugs
bevacizumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01739218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01739218.